The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Rare disease-focused Sarepta Therapeutics Inc. netted $477.5mm through the follow-on public offering of 3.8mm common shares at $131 each. The company will use the proceeds for R&D and manufacturing activities and to finance capital expenditures and capacity expansions.


+ Show All | – Hide All

Financials


Click a figure for comparable deals.

Overview
Potential Deal Value $477.53mm
Transactions 1 of 1 (11/2018)
Equity $477.53mm
Total Line Value $477.53mm
Price/Share $131.00
# Shares 3.82mm
Shares Outstanding 70.51mm
Post-Money Valuation $9,236.86mm
Gross Proceeds $500.03mm
Net Proceeds $477.53mm

Deal Information


Click a keyword for comparable deals.

Deal Industry Biotechnology
Antisense, Oligonucleotides
Gene Therapy, Cell Therapy
Large Molecule
Pharmaceuticals
Vaccines
Deal Status Final
Deal Type Financing
FOPO

Company Information


Click a keyword for comparable companies.

Sarepta Therapeutics Inc. www.sarepta.com | Ticker: SRPT
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
MA
Industry Biotechnology
Antisense, Oligonucleotides
Gene Therapy, Cell Therapy
Large Molecule
Pharmaceuticals
Vaccines
Ownership Public
Therapeutic Area(s) of Focus Infectious & Viral Diseases
Musculoskeletal & Connective Tissue Disorders
Neurology, Nervous System
Alias(es) AVI BioPharma Inc.
Company Advisors (Underwriters) Cantor Fitzgerald & Co.
Cowen & Co. LLC
Credit Suisse Group
Goldman Sachs & Co.
HC Wainwright & Co.
JP Morgan & Co.
Nomura Securities International Inc.
Robert W. Baird & Co. Inc.
William Blair & Co.